MENU
+Compare
NBIX
Stock ticker: NASDAQ
AS OF
Nov 26, 04:59 PM (EDT)
Price
$151.62
Change
+$8.09 (+5.64%)
Capitalization
14.31B

NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States... Show more

Industry: #Biotechnology
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NBIX with price predictions
Nov 25, 2025

NBIX in upward trend: price rose above 50-day moving average on November 25, 2025

NBIX moved above its 50-day moving average on November 25, 2025 date and that indicates a change from a downward trend to an upward trend. In of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where NBIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on November 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on November 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for NBIX crossed bearishly below the 50-day moving average on November 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NBIX broke above its upper Bollinger Band on November 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.764) is normal, around the industry mean (16.491). P/E Ratio (34.255) is within average values for comparable stocks, (72.893). Projected Growth (PEG Ratio) (0.360) is also within normal values, averaging (1.950). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (5.467) is also within normal values, averaging (55.675).

View a ticker or compare two or three
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NBIX is expected to report earnings to fall 13.82% to $1.87 per share on February 11

Neurocrine Biosciences NBIX Stock Earnings Reports
Q4'25
Est.
$1.87
Q3'25
Beat
by $0.58
Q2'25
Beat
by $0.69
Q1'25
Missed
by $0.07
Q4'24
Beat
by $0.12
The last earnings report on October 28 showed earnings per share of $2.17, beating the estimate of $1.59. With 681.16K shares outstanding, the current market capitalization sits at 14.31B.
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
1400
Web
https://www.neurocrine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ARVR48.031.71
+3.70%
First Trust Indxx Metaverse ETF
GURU62.560.92
+1.49%
Global X Guru™ ETF
GLOV57.340.60
+1.05%
Goldman Sachs ActBt Wld Lw Vl Ps Eq ETF
XV26.190.14
+0.53%
Simplify Target 15 Distribution ETF
FCOR48.350.10
+0.21%
Fidelity Corporate Bond ETF

NBIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with CGC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+1.61%
CGC - NBIX
33%
Loosely correlated
+4.39%
TEVA - NBIX
33%
Poorly correlated
+0.89%
ELAN - NBIX
30%
Poorly correlated
+1.47%
EOLS - NBIX
30%
Poorly correlated
+3.56%
AQST - NBIX
29%
Poorly correlated
+5.36%
More

Groups containing NBIX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+1.61%
Pharmaceuticals: Generic
industry (214 stocks)
46%
Loosely correlated
+0.65%